Results 41 to 50 of about 681,060 (251)

Antidepressant discontinuation in treatment resistant depression

Contemporary Clinical Trials Communications, 2019
Treatment-resistant depression (TRD) is a growing problem in psychiatric practice with some 15–20% of depressed patients becoming chronically depressed and perhaps as many as 40% in tertiary settings.
Ziad A. Ali, Sharon Nuss, Rif S. El-Mallakh   +2 more
doaj   +1 more source

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.

American Journal of Psychiatry, 2019
OBJECTIVE About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective ...
V. Popova, E. Daly, M. Trivedi, K. Cooper, R. Lane, P. Lim, Christine Mazzucco, D. Hough, M. Thase, R. Shelton, P. Molero, E. Vieta, M. Bajbouj, H. Manji, W. Drevets, Jaskaran Singh   +15 more
semanticscholar   +1 more source

Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).

Psychiatry Research, 2023
Treatment-resistant depression (TRD) represents a severe clinical condition with high social and economic costs. Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD by EMA and FDA, but data about predictors of response are still lacking ...
M. Pettorruso, Roberto Guidotti, G. d’Andrea, Luisa De Risio, A. D’Andrea, Stefania Chiappini, Rosalba Carullo, S. Barlati, R. Zanardi, G. Rosso, S. De Filippis, M. Di Nicola, I. Andriola, M. Marcatili, G. Nicolò, V. Martiadis, R. Bassetti, D. Nucifora, P. De Fazio, J. Rosenblat, M. Clerici, Bernardo Maria Dell'Osso, A. Vita, L. Marzetti, S. Sensi, G. Di Lorenzo, R. McIntyre, G. Martinotti   +27 more
semanticscholar   +1 more source

Neuromodulation for treatment-resistant depression [PDF]

F1000 Medicine Reports, 2012
Treatment-resistant depression affects at least 1-3% of the US population. This article reviews the current state of focal neuromodulation therapies for treatment-resistant depression, focusing on those treatments published clinical data. These include transcranial magnetic stimulation, transcranial direct current stimulation, magnetic seizure therapy,
Holtzheimer, Paul E., Mayberg, Helen S.
openaire   +2 more sources

Body mass index and inflammation in depression and treatment-resistant depression: a Mendelian randomisation study

BMC Medicine, 2023
Background Major depressive disorder (MDD) has a significant impact on global burden of disease. Complications in clinical management can occur when response to pharmacological modalities is considered inadequate and symptoms persist (treatment-resistant
V. Karageorgiou, F. Casanova, Jessica O’Loughlin, Harry D. Green, T. McKinley, Jack Bowden, Jessica Tyrrell   +6 more
semanticscholar   +1 more source

Closed-loop neuromodulation in an individual with treatment-resistant depression

Nature Medicine, 2021
Deep brain stimulation is a promising treatment for neuropsychiatric conditions such as major depression. It could be optimized by identifying neural biomarkers that trigger therapy selectively when symptom severity is elevated.
K. Scangos, A. Khambhati, Patrick M Daly, Ghassan S. Makhoul, L. Sugrue, H. Zamanian, Tony X. Liu, V. Rao, Kristin K. Sellers, Heather E. Dawes, P. Starr, A. Krystal, E. Chang   +12 more
semanticscholar   +1 more source

Case Report: Use of Subcutaneous Midazolam During an Episode of Catatonia

Frontiers in Psychiatry, 2021
Midazolam is a benzodiazepine (BZD) mainly used in anesthetic induction due to its pharmacokinetic features. Its place in the therapeutic management of catatonia remains to be determined. Here we present the case of a 65-year-old man who presented with a
Valentin Raymond, Etienne Véry, Adeline Jullien, Fréderic Eyvrard, Loic Anguill, Antoine Yrondi   +5 more
doaj   +1 more source

Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression

JAMA Network Open, 2022
Key Points Question Does 6 weeks of minocycline treatment as add-on to standard antidepressant treatment reduce depressive symptoms in patients with treatment-resistant depression? Findings In this randomized clinical trial of 168 patients with treatment-
J. Hellmann‐Regen, Vera Clemens, M. Grözinger, J. Kornhuber, A. Reif, D. Prvulovic, R. Goya-Maldonado, J. Wiltfang, O. Gruber, C. Schüle, F. Padberg, M. Ising, M. Uhr, T. Friede, C. Huber, André Manook, T. Baghai, R. Rupprecht, I. Heuser   +18 more
semanticscholar   +1 more source

Predictors of prospective suicide attempts in a group at risk of personality disorder following self-poisoning

Frontiers in Psychiatry, 2023
BackgroundPatients with personality disorder (PD) are at risk for suicidal behavior and are frequently admitted for this reason to emergency departments.
Lionel Cailhol, Mariève Marcoux, Anjali Mathur, Antoine Yrondi, Philippe Birmes   +4 more
doaj   +1 more source

Avidin is evolutionarily conserved in fish but dispensable for development and resistance against Streptococcus agalactiae in zebrafish

FEBS Open Bio, EarlyView.
The presence of biotin‐binding avidin proteins in fish and their biological significance are poorly characterized. We cataloged fish avidins and demonstrate that they are widely present and evolutionarily conserved. We created avd knockout zebrafish and show that zebavidin is dispensable for development and that resistance of avd knockout embryos in ...
Anni K. Saralahti, Markus J. T. Ojanen, Mataleena Parikka, Otto Kauko, Mika Rämet, Vesa P. Hytönen   +5 more
wiley   +1 more source